Alastair Peter Greystoke

List of Publications by Year
in descending order

45	4,085	304743 22	265206 42
papers	citations	h-index	g-index

46	46	46	6496
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Prevalence of Epidermal Growth Factor Receptor Exon 20 Insertion Mutations in Non-small-Cell Lung Cancer in Europe: A Pragmatic Literature Review and Meta-analysis. Targeted Oncology, 2022, 17, 153-166.	3.6	15
2	Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial. Lancet Oncology, The, 2022, 23, 540-552.	10.7	25
3	Randomised controlled trial of intermittent vs continuous energy restriction during chemotherapy for early breast cancer. British Journal of Cancer, 2022, 126, 1157-1167.	6.4	7
4	Re-evaluating Subsequent Treatment Options in Non-small Cell Lung Cancer in the Era of Immune Checkpoint Inhibitors. Clinical Oncology, 2022, , .	1.4	0
5	TARGET National: A U.K.-wide liquid-based molecular profiling program to enhance recruitment to early-phase trials.. Journal of Clinical Oncology, 2022, 40, TPS3163-TPS3163.	1.6	2
6	Atezolizumab and bevacizumab in patients with relapsed mesothelioma: MIST4â€"a phase IIa trial with cellular and molecular correlates of efficacy.. Journal of Clinical Oncology, 2022, 40, 8560-8560.	1.6	1
7	Hypofractionated chemoradiotherapy for locally advanced non-small cell lung cancer: Is split-dose chemotherapy safer than full dose chemotherapy?. Radiotherapy and Oncology, 2021, 154, e13.	0.6	1
8	A phase II trial of abemaciclib in patients with p16ink4a negative, relapsed mesothelioma.. Journal of Clinical Oncology, 2021, 39, 8558-8558.	1.6	7
9	An open-label, multicenter phase I/IIa study evaluating the safety and clinical activity of clonal neoantigen reactive T cells in patients with advanced non-small cell lung cancer (CHIRON).. Journal of Clinical Oncology, 2021, 39, TPS9138-TPS9138.	1.6	2
10	P-OGC20â€ƒCan prehabilitation prevent development of sarcopenia during neoadjuvant chemotherapy for oesophagogastric adenocarcinoma?. British Journal of Surgery, 2021, 108, .	0.3	1
11	Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC: The AURA Leptomeningeal Metastases Analysis. Journal of Thoracic Oncology, 2020, 15, 637-648.	1.1	83
12	The National Lung Matrix Trial of personalized therapy in lung cancer. Nature, 2020, 583, 807-812.	27.8	96
13	Phase 1/2a trial of intravenous BAL101553, a novel controller of the spindle assembly checkpoint, in advanced solid tumours. British Journal of Cancer, 2020, 123, 1360-1369.	6.4	10
14	Sequential chemotherapy followed by radical thoracic radiotherapy (50 Gy in 25 fractions) in limited stage small cell lung cancer. Ecancermedicalscience, 2020, 14, 1019.	1.1	0
15	Alternative splicing in lung cancer. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2019, 1862, 194388.	1.9	47
16	A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours. British Journal of Cancer, 2019, 120, 975-981.	6.4	61
17	Cost-effectiveness of osimertinib in the UK for advanced EGFR-T790M non-small cell lung cancer. Journal of Medical Economics, 2018, 21, 113-121.	2.1	30
18	The Effect of Food or Omeprazole on the Pharmacokinetics of Osimertinib in Patients With Nonâ€Smallâ€Cell Lung Cancer and in Healthy Volunteers. Journal of Clinical Pharmacology, 2018, 58, 474-484.	2.0	41

#	Article	IF	Citations
19	Management of ceritinib therapy and adverse events in patients with ALK -rearranged non-small cell lung cancer. Lung Cancer, 2017, 111, 51-58.	2.0	15
20	SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting. British Journal of Cancer, 2017, 117, 938-946.	6.4	18
21	ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Nonâ€“Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology, 2017, 12, 1357-1367.	1.1	144
22	A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours. European Journal of Cancer, 2016, 68, 1-10.	2.8	9
23	Development of a circulating miRNA assay to monitor tumor burden: From mouse to man. Molecular Oncology, 2016, 10, 282-291.	4.6	18
24	Spindle cell carcinoma of the head and neck region: treatment and outcomes of 15 patients. Ecancermedicalscience, 2015, 9, 594.	1.1	17
25	First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014. Clinical Cancer Research, 2015, 21, 3412-3419.	7.0	101
26	The use of circulating biomarkers in early clinical trials in patients with cancer. Biomarkers in Medicine, 2015, 9, 1011-1023.	1.4	2
27	An introduction to stratified medicine. Drug Discovery Today, 2015, 20, 1409-1413.	6.4	2
28	A phase Ib dose-escalation study of GSK2256098 (FAKi) plus trametinib (MEKi) in patients with selected advanced solid tumors.. Journal of Clinical Oncology, 2015, 33, 2593-2593.	1.6	7
29	A Phase I, Dose-Escalation Study of the Multitargeted Receptor Tyrosine Kinase Inhibitor, Golvatinib, in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2014, 20, 6284-6294.	7.0	24
30	Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer. Nature Medicine, 2014, 20, 897-903.	30.7	608
31	Clinical Significance and Molecular Characteristics of Circulating Tumor Cells and Circulating Tumor Microemboli in Patients With Small-Cell Lung Cancer. Journal of Clinical Oncology, 2012, 30, 525-532.	1.6	755
32	A Pilot Study Assessing the Prognostic Value of CK18 and nDNA Biomarkers in Severe Sepsis Patients. Clinical Drug Investigation, 2012, 32, 179-187.	2.2	25
33	Biomarkers of cell death applicable to early clinical trials. Experimental Cell Research, 2012, 318, 1252-1259.	2.6	17
34	Evaluation and Prognostic Significance of Circulating Tumor Cells in Patients With Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2011, 29, 1556-1563.	1.6	788
35	Assessment of circulating biomarkers for potential pharmacodynamic utility in patients with lymphoma. British Journal of Cancer, 2011, 104, 719-725.	6.4	48
36	A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours. British Journal of Cancer, 2011, 104, 750-755.	6.4	113

#	Article	IF	Citations
37	Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer. Breast Cancer Research and Treatment, 2010, 120, 461-467.	2.5	191
38	Evaluation of Circulating Tumor Cells and Serological Cell Death Biomarkers in Small Cell Lung Cancer Patients Undergoing Chemotherapy. American Journal of Pathology, 2009, 175, 808-816.	3.8	223
39	Isolation and Extraction of Circulating Tumor DNA from Patients with Small Cell Lung Cancer. Annals of the New York Academy of Sciences, 2008, 1137, 98-107.	3.8	90
40	Biomarkers of apoptosis. British Journal of Cancer, 2008, 99, 841-846.	6.4	101
41	Biomarker method validation in anticancer drug development. British Journal of Pharmacology, 2008, 153, 646-656.	5.4	114
42	Optimisation of circulating biomarkers of cell death for routine clinical use. Annals of Oncology, 2008, 19, 990-995.	1.2	68
43	Serum biomarkers of apoptosis. European Journal of Cancer, Supplement, 2007, 5, 115-127.	2.2	0
44	Update on tubulin-binding agents. Pathologie Et Biologie, 2006, 54, 72-84.	2.2	134
45	Phase I/II study of DHAâ€“paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours. British Journal of Cancer, 2004, 91, 1651-1655.	6.4	23